Taken together, our study demonstrated that the newly developed diagnostic panel consisting of SOX2OT, ANRIL, CEA, CYFRA21‐1, and SCCA could be valuable in NSCLC diagnosis. This evidence concerns the gene CDKN2B-AS1 and non-small cell lung carcinoma.